Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Molecular Targeted Therapy"" wg kryterium: Temat


Tytuł:
Nephrotoxicity of targeted therapy used to treat lung cancer.
Autorzy:
Li Q; Department of Nephrology, Blood Purification Center, Zhongshan People's Hospital, Zhongshan, China.
Lin J; Department of Nephrology, Blood Purification Center, Zhongshan People's Hospital, Zhongshan, China.; Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Hao G; Department of Nephrology, Blood Purification Center, Zhongshan People's Hospital, Zhongshan, China.
Xie A; Department of Nephrology, Blood Purification Center, Zhongshan People's Hospital, Zhongshan, China.
Liu S; Department of Nephrology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
Tang B; Department of Nephrology, Blood Purification Center, Zhongshan People's Hospital, Zhongshan, China.
Pokaż więcej
Źródło:
Frontiers in immunology [Front Immunol] 2024 Jul 04; Vol. 15, pp. 1369118. Date of Electronic Publication: 2024 Jul 04 (Print Publication: 2024).
Typ publikacji:
Journal Article; Review
MeSH Terms:
Lung Neoplasms*/drug therapy
Molecular Targeted Therapy*/adverse effects
Protein Kinase Inhibitors*/adverse effects
Protein Kinase Inhibitors*/therapeutic use
Antineoplastic Agents*/adverse effects
Antineoplastic Agents*/therapeutic use
Humans ; Anaplastic Lymphoma Kinase/antagonists & inhibitors ; ErbB Receptors/antagonists & inhibitors ; Animals ; Kidney Diseases/chemically induced ; Kidney/drug effects ; Kidney/pathology ; Kidney/metabolism ; Carcinoma, Non-Small-Cell Lung/drug therapy
Czasopismo naukowe
Tytuł:
Molecular Targeting of the Isocitrate Dehydrogenase Pathway and the Implications for Cancer Therapy.
Autorzy:
Ivanov S; Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, FL 33028, USA.
Nano O; Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, FL 33028, USA.
Hana C; Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, FL 33028, USA.
Bonano-Rios A; Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, FL 33028, USA.
Hussein A; Memorial Cancer Institute, Memorial Healthcare System, Pembroke Pines, FL 33028, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jul 04; Vol. 25 (13). Date of Electronic Publication: 2024 Jul 04.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Isocitrate Dehydrogenase*/genetics
Isocitrate Dehydrogenase*/antagonists & inhibitors
Isocitrate Dehydrogenase*/metabolism
Neoplasms*/genetics
Neoplasms*/drug therapy
Neoplasms*/metabolism
Molecular Targeted Therapy*
Humans ; Mutation ; Animals ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/pharmacology
Czasopismo naukowe
Tytuł:
Multiple myeloma: signaling pathways and targeted therapy.
Autorzy:
Lu Q; Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yang D; College of Veterinary Medicine, Shaanxi Center of Stem Cells Engineering and Technology, Northwest A&F University, Yangling, 712100, China.
Li H; Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Niu T; Department of Hematology, State Key Laboratory of Biotherapy and Cancer Center, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. .
Tong A; State Key Laboratory of Biotherapy and Cancer Center, Research Unit of Gene and Immunotherapy, Chinese Academy of Medical Sciences, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China. .; Frontiers Medical Center, Tianfu Jincheng Laboratory, Chengdu, 610212, China. .
Pokaż więcej
Źródło:
Molecular biomedicine [Mol Biomed] 2024 Jul 04; Vol. 5 (1), pp. 25. Date of Electronic Publication: 2024 Jul 04.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Multiple Myeloma*/drug therapy
Multiple Myeloma*/therapy
Multiple Myeloma*/pathology
Multiple Myeloma*/metabolism
Signal Transduction*/drug effects
Molecular Targeted Therapy*/methods
Humans ; Animals ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/pharmacology ; Tumor Microenvironment/drug effects
Czasopismo naukowe
Tytuł:
Erratum to: Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies.
Autorzy:
Woolston DW; Fred Hutchinson Cancer Center.
Lee ND; University of Washington, Seattle, WA.
Shadman M; Fred Hutchinson Cancer Center; University of Washington, Seattle, WA.
Latorre-Esteves E; University of Washington, Seattle, WA.
Tee XR; University of Washington, Seattle, WA.
Fredrickson J; University of Washington, Seattle, WA.
Kohrn BF; University of Washington, Seattle, WA.
Ujjani C; Fred Hutchinson Cancer Center; University of Washington, Seattle, WA.
Eckel A; University of Washington, Seattle, WA.
Till B; Fred Hutchinson Cancer Center; University of Washington, Seattle, WA.
Fang M; Fred Hutchinson Cancer Center; University of Washington, Seattle, WA.
Radich J; Fred Hutchinson Cancer Center; University of Washington, Seattle, WA.
Bozic I; Fred Hutchinson Cancer Center; University of Washington, Seattle, WA.
Risques RA; University of Washington, Seattle, WA.
Yeung CCS; Fred Hutchinson Cancer Center; University of Washington, Seattle, WA. .
Pokaż więcej
Źródło:
Haematologica [Haematologica] 2024 Jul 01; Vol. 109 (7), pp. 2378. Date of Electronic Publication: 2024 Jul 01.
Typ publikacji:
Published Erratum; Journal Article
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/genetics
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/mortality
Mutation*
Drug Resistance, Neoplasm*/genetics
Molecular Targeted Therapy*
Humans ; High-Throughput Nucleotide Sequencing
Czasopismo naukowe
Tytuł:
PAK4-targeted PROTACs in clear cell renal cell carcinoma: a two-for-one targeted and immune therapy?
Autorzy:
Bakouny Z; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: .
Braun DA; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Reznik E; Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hakimi AA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pokaż więcej
Źródło:
EBioMedicine [EBioMedicine] 2024 Jul; Vol. 105, pp. 105218. Date of Electronic Publication: 2024 Jun 25.
Typ publikacji:
Letter; Journal Article
MeSH Terms:
Carcinoma, Renal Cell*/drug therapy
Carcinoma, Renal Cell*/metabolism
Carcinoma, Renal Cell*/pathology
Kidney Neoplasms*/drug therapy
Kidney Neoplasms*/metabolism
Kidney Neoplasms*/pathology
Molecular Targeted Therapy*
Humans ; p21-Activated Kinases/metabolism ; p21-Activated Kinases/genetics ; p21-Activated Kinases/antagonists & inhibitors ; Immunotherapy/methods ; Proteolysis Targeting Chimera
Czasopismo naukowe
Tytuł:
Targeted Therapies in Low-Grade Serous Ovarian Cancers.
Autorzy:
Gonzalez A; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, M-210 Starling Loving Hall, 320 W. 10th Avenue, Columbus, OH, 43210, USA.
Nagel CI; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, M-210 Starling Loving Hall, 320 W. 10th Avenue, Columbus, OH, 43210, USA. .
Haight PJ; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, M-210 Starling Loving Hall, 320 W. 10th Avenue, Columbus, OH, 43210, USA.
Pokaż więcej
Źródło:
Current treatment options in oncology [Curr Treat Options Oncol] 2024 Jul; Vol. 25 (7), pp. 854-868. Date of Electronic Publication: 2024 Jun 13.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/pathology
Molecular Targeted Therapy*/methods
Neoplasm Grading*
Cystadenocarcinoma, Serous*/drug therapy
Cystadenocarcinoma, Serous*/pathology
Cystadenocarcinoma, Serous*/therapy
Humans ; Female ; Treatment Outcome ; Combined Modality Therapy/adverse effects ; Disease Management ; Biomarkers, Tumor ; Neoplasm Staging ; Clinical Trials as Topic
Czasopismo naukowe
Tytuł:
Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer.
Autorzy:
Abdalla AS; Department of Internal Medicine, AdventHealth, Sebring, Florida, USA.
Rahman M; Department of Pathology, Stanford University, Stanford, CA, USA.
Khan SA; Division of Oncology, Department of Medicine and Stanford Cancer Institute, Stanford University, 780 Welch Road, CJ250L, Stanford, CA, 94304, USA. .
Pokaż więcej
Źródło:
Current treatment options in oncology [Curr Treat Options Oncol] 2024 Jul; Vol. 25 (7), pp. 869-884. Date of Electronic Publication: 2024 Jun 12.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Thyroid Carcinoma, Anaplastic*/therapy
Thyroid Carcinoma, Anaplastic*/diagnosis
Thyroid Carcinoma, Anaplastic*/drug therapy
Thyroid Carcinoma, Anaplastic*/pathology
Molecular Targeted Therapy*
Neoplasm Recurrence, Local*/drug therapy
Humans ; Biomarkers, Tumor ; Disease Management ; Mutation ; Thyroid Neoplasms/therapy ; Thyroid Neoplasms/drug therapy ; Thyroid Neoplasms/diagnosis ; Thyroid Neoplasms/pathology ; Neoplasm Metastasis ; Treatment Outcome ; Disease Susceptibility
Czasopismo naukowe
Tytuł:
What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?
Autorzy:
Forester E; Division of Breast Surgical Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Rowan-Virtua School of Osteopathic Medicine, Stratford, New Jersey.
Belsare A; Division of Breast Surgical Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania.
Kim DW; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Whitaker K; Department of Medical Oncology, MedStar Health, Washington, District of Columbia.
Obeid E; Hackensack Meridian Health Network, Edison, New Jersey.
Goldstein LJ; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Bleicher RJ; Division of Breast Surgical Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Daly MB; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Williams AD; Division of Breast Surgical Oncology, Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: .
Pokaż więcej
Źródło:
The Journal of surgical research [J Surg Res] 2024 Jul; Vol. 299, pp. 217-223. Date of Electronic Publication: 2024 May 21.
Typ publikacji:
Journal Article
MeSH Terms:
Receptor, ErbB-2*/genetics
Receptor, ErbB-2*/metabolism
Receptor, ErbB-2*/analysis
BRCA1 Protein*/genetics
BRCA2 Protein*/genetics
Molecular Targeted Therapy*/methods
Humans ; Female ; Retrospective Studies ; Middle Aged ; Adult ; Aged ; Triple Negative Breast Neoplasms/genetics ; Triple Negative Breast Neoplasms/drug therapy ; Germ-Line Mutation ; Breast Neoplasms/genetics ; Breast Neoplasms/drug therapy ; Breast Neoplasms/pathology
Czasopismo naukowe
Tytuł:
Targeted therapy for immune mediated skin diseases. What should a dermatologist know?
Autorzy:
López E; Department of Dermatology, Facultad de Medicina Universidad del Desarrollo-Clínica Alemana de Santiago, Santiago, Chile.
Cabrera R; Department of Dermatology, Facultad de Medicina Universidad del Desarrollo-Clínica Alemana de Santiago, Santiago, Chile. Electronic address: .
Lecaros C; Department of Dermatology, Facultad de Medicina Universidad del Desarrollo-Clínica Alemana de Santiago, Santiago, Chile.
Pokaż więcej
Źródło:
Anais brasileiros de dermatologia [An Bras Dermatol] 2024 Jul-Aug; Vol. 99 (4), pp. 546-567. Date of Electronic Publication: 2024 Mar 22.
Typ publikacji:
Journal Article; Systematic Review
MeSH Terms:
Molecular Targeted Therapy*
Skin Diseases*/drug therapy
Humans ; Antibodies, Monoclonal/therapeutic use ; Dermatologists ; Janus Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
Advancements in combining targeted therapy and immunotherapy for colorectal cancer.
Autorzy:
Singh M; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .
Morris VK; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bandey IN; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hong DS; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kopetz S; Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: .
Pokaż więcej
Źródło:
Trends in cancer [Trends Cancer] 2024 Jul; Vol. 10 (7), pp. 598-609. Date of Electronic Publication: 2024 May 31.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Colorectal Neoplasms*/therapy
Colorectal Neoplasms*/immunology
Colorectal Neoplasms*/pathology
Molecular Targeted Therapy*/methods
Immunotherapy*/methods
Humans ; Combined Modality Therapy/methods ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations.
Autorzy:
Xiong K; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China; Department of Cancer Center, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China.
Yang Y; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China.
Yang Y; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China.
Wang Z; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China.
Liu Y; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China.
Duo H; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China.
Yuan X; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China.
Xiao Y; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China.
Xiao H; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China.
Yang X; Department of Cancer Center, Daping Hospital, Army Medical University, Chongqing 400042, China. Electronic address: .
Pokaż więcej
Źródło:
Neoplasia (New York, N.Y.) [Neoplasia] 2024 Jul; Vol. 53, pp. 101006. Date of Electronic Publication: 2024 May 17.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Carcinoma, Non-Small-Cell Lung*/mortality
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Lung Neoplasms*/mortality
Mutation*
Biomarkers, Tumor*/genetics
Response Evaluation Criteria in Solid Tumors*
Molecular Targeted Therapy*/methods
Neoplasm Staging*
Humans ; Female ; Male ; Middle Aged ; Aged ; Retrospective Studies ; Adult ; Protein Kinase Inhibitors/therapeutic use ; Aged, 80 and over ; Treatment Outcome ; Prognosis
Czasopismo naukowe
Tytuł:
Emerging targeted therapies and strategies to overcome resistance in biliary tract cancers.
Autorzy:
Demir T; Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine1, Chicago, IL 60611, USA. Electronic address: .
Moloney C; Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine1, Chicago, IL 60611, USA.
Mahalingam D; Developmental Therapeutics, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine1, Chicago, IL 60611, USA.
Pokaż więcej
Źródło:
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2024 Jul; Vol. 199, pp. 104388. Date of Electronic Publication: 2024 May 15.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Biliary Tract Neoplasms*/drug therapy
Biliary Tract Neoplasms*/pathology
Drug Resistance, Neoplasm*/drug effects
Molecular Targeted Therapy*/methods
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
Enhancing treatment strategies for small bowel cancer: a clinical review of targeted therapy and immunotherapy approaches.
Autorzy:
Ebrahimpour M; School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Hosseinzadeh H; School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Abedi F; Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Nodeh MM; Department of Hematology and Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Allahyari A; Department of Hematology and Oncology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Sahebkar A; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Arasteh O; Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. .
Pokaż więcej
Źródło:
Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2024 Jul; Vol. 397 (7), pp. 4601-4614. Date of Electronic Publication: 2024 Feb 08.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Immunotherapy*/methods
Molecular Targeted Therapy*
Intestinal Neoplasms*/therapy
Intestinal Neoplasms*/immunology
Intestinal Neoplasms*/drug therapy
Humans ; Adenocarcinoma/therapy ; Adenocarcinoma/immunology ; Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Intestine, Small/immunology ; Intestine, Small/pathology ; Neuroendocrine Tumors/therapy ; Neuroendocrine Tumors/immunology ; Neuroendocrine Tumors/drug therapy
Czasopismo naukowe
Tytuł:
Liquid-based cytology specimens for next-generation sequencing in lung adenocarcinoma: challenges and evaluation of targeted therapy.
Autorzy:
Xiao X; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Sun Z; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Liang S; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Li W; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Guo H; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Zhao H; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Zhao L; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Ma H; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Sun Y; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Wang C; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Chang X; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Zhang Z; Cytopathology Section, Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 Jun 20; Vol. 24 (1), pp. 749. Date of Electronic Publication: 2024 Jun 20.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma of Lung*/genetics
Adenocarcinoma of Lung*/drug therapy
Adenocarcinoma of Lung*/pathology
High-Throughput Nucleotide Sequencing*/methods
Lung Neoplasms*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/pathology
ErbB Receptors*/genetics
Protein Kinase Inhibitors*/therapeutic use
Molecular Targeted Therapy*/methods
Mutation*
Humans ; Female ; Male ; Middle Aged ; Retrospective Studies ; Aged ; Adult ; Liquid Biopsy/methods ; Aged, 80 and over ; Biomarkers, Tumor/genetics ; Cytology
Czasopismo naukowe
Tytuł:
Multifaceted effects of LRP6 in cancer: exploring tumor development, immune modulation and targeted therapies.
Autorzy:
Li L; Department of Hematology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Zhao L; Laboratory of Clinical Molecular Cytogenetics and Immunology, The First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China.; Gansu Key Laboratory of Genetic Study of Hematopathy, Lanzhou, Gansu, People's Republic of China.
Yang J; The First School of Clinical Medicine, Lanzhou University, Lanzhou, Gansu, People's Republic of China.
Zhou L; Laboratory of Clinical Molecular Cytogenetics and Immunology, The First Hospital of Lanzhou University, Lanzhou, Gansu, People's Republic of China. .; Gansu Key Laboratory of Genetic Study of Hematopathy, Lanzhou, Gansu, People's Republic of China. .
Pokaż więcej
Źródło:
Medical oncology (Northwood, London, England) [Med Oncol] 2024 Jun 19; Vol. 41 (7), pp. 180. Date of Electronic Publication: 2024 Jun 19.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Low Density Lipoprotein Receptor-Related Protein-6*/metabolism
Neoplasms*/pathology
Neoplasms*/metabolism
Neoplasms*/drug therapy
Neoplasms*/immunology
Molecular Targeted Therapy*/methods
Humans ; Tumor Microenvironment/immunology ; Wnt Signaling Pathway ; Animals
Czasopismo naukowe
Tytuł:
Cell and molecular targeted therapies for diabetic retinopathy.
Autorzy:
Reddy SK; Centre for Molecular Neurosciences, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India.
Devi V; Department of Pharmacology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India.
Seetharaman ATM; Department of Ophthalmology, The University of Tennessee Health Science Center, Memphis, TN, United States.
Shailaja S; Department of Ophthalmology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India.
Bhat KMR; Department of Anatomy, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India.
Gangaraju R; Department of Ophthalmology, The University of Tennessee Health Science Center, Memphis, TN, United States.; Department of Anatomy & Neurobiology, The University of Tennessee Health Science Center, Memphis, TN, United States.
Upadhya D; Centre for Molecular Neurosciences, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, India.
Pokaż więcej
Źródło:
Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2024 Jun 14; Vol. 15, pp. 1416668. Date of Electronic Publication: 2024 Jun 14 (Print Publication: 2024).
Typ publikacji:
Journal Article; Review
MeSH Terms:
Diabetic Retinopathy*/drug therapy
Diabetic Retinopathy*/metabolism
Molecular Targeted Therapy*/methods
Humans ; Animals ; Cell- and Tissue-Based Therapy/methods ; Vascular Endothelial Growth Factor A/antagonists & inhibitors ; Vascular Endothelial Growth Factor A/metabolism
Czasopismo naukowe
Tytuł:
Trop2-targeted therapies in solid tumors: advances and future directions.
Autorzy:
Liu X; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China.; Qingdao Cancer Institute, Qingdao, 266071, China.
Ma L; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China.; Qingdao Cancer Institute, Qingdao, 266071, China.
Li J; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China.; Qingdao Cancer Institute, Qingdao, 266071, China.
Sun L; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China.; Qingdao Cancer Institute, Qingdao, 266071, China.
Yang Y; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China.; Qingdao Cancer Institute, Qingdao, 266071, China.
Liu T; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China.; Qingdao Cancer Institute, Qingdao, 266071, China.
Xing D; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China.; Qingdao Cancer Institute, Qingdao, 266071, China.; School of Life Sciences, Tsinghua University, Beijing, 100084, China.
Yan S; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China.; Qingdao Cancer Institute, Qingdao, 266071, China.
Zhang M; The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao 266071, China.; Qingdao Cancer Institute, Qingdao, 266071, China.
Pokaż więcej
Źródło:
Theranostics [Theranostics] 2024 Jun 11; Vol. 14 (9), pp. 3674-3692. Date of Electronic Publication: 2024 Jun 11 (Print Publication: 2024).
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antigens, Neoplasm*/immunology
Cell Adhesion Molecules*/antagonists & inhibitors
Cell Adhesion Molecules*/metabolism
Immunoconjugates*/therapeutic use
Immunoconjugates*/pharmacology
Molecular Targeted Therapy*/methods
Neoplasms*/drug therapy
Neoplasms*/therapy
Humans ; Immunotherapy/methods ; Animals ; Cancer Vaccines/therapeutic use
Czasopismo naukowe
Tytuł:
Signaling pathways in colorectal cancer implications for the target therapies.
Autorzy:
Song Y; Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China.
Chen M; West China School of Medicine, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China.
Wei Y; West China School of Medicine, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China.
Ma X; Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China. .
Shi H; Department of Biotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan, 610041, People's Republic of China. .
Pokaż więcej
Źródło:
Molecular biomedicine [Mol Biomed] 2024 Jun 07; Vol. 5 (1), pp. 21. Date of Electronic Publication: 2024 Jun 07.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Colorectal Neoplasms*/genetics
Colorectal Neoplasms*/metabolism
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/therapy
Colorectal Neoplasms*/immunology
Signal Transduction*/drug effects
Molecular Targeted Therapy*/methods
Humans ; Animals ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/pharmacology
Czasopismo naukowe
Tytuł:
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.
Autorzy:
Lin CH; Department of Internal Medicine, Case Western Reserve University, MetroHealth Campus, Cleveland, OH 44109, USA.
Tariq MJ; Department of Hematology-Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA.
Ullah F; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.
Sannareddy A; Department of Hematology-Oncology, UT Southwestern, Dallas, TX 75235, USA.
Khalid F; Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA.
Abbas H; Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Bader A; School of Medicine, University of Missouri-Kansas City, Kansas City, MO 64110, USA.
Samaras C; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.
Valent J; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.
Khouri J; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.
Anwer F; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.
Raza S; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.
Dima D; Department of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Fred Hutchinson Cancer Center, University of Washington, Seattle, WA 98109, USA.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jun 04; Vol. 25 (11). Date of Electronic Publication: 2024 Jun 04.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Multiple Myeloma*/drug therapy
Multiple Myeloma*/metabolism
Molecular Targeted Therapy*/methods
Humans ; Antineoplastic Agents/therapeutic use ; Animals
Czasopismo naukowe
Tytuł:
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Autorzy:
Stricker T; Tennessee Oncology, Nashville, TN, USA.; OneOncology LLC, Nashville, TN, USA.
Jain N; OneOncology LLC, Nashville, TN, USA.
Ma E; Genentech, Inc., South San Francisco, CA, USA.
Yu E; Genentech, Inc., South San Francisco, CA, USA.
Wang R; Genentech, Inc., South San Francisco, CA, USA.
Schuldt R; Genentech, Inc., South San Francisco, CA, USA.
Price R; Genentech, Inc., South San Francisco, CA, USA.
Szado T; Genentech, Inc., South San Francisco, CA, USA.
Sussell J; Genentech, Inc., South San Francisco, CA, USA.
Ogale S; Genentech, Inc., South San Francisco, CA, USA.
Lin V; OneOncology LLC, Nashville, TN, USA.; Mary Bird Perkins Cancer Center, Baton Rouge, LA, USA.
Arrowsmith E; Tennessee Oncology, Nashville, TN, USA.; OneOncology LLC, Nashville, TN, USA.
Slater D; OneOncology LLC, Nashville, TN, USA.; Eastern Connecticut Hematology and Oncology, Norwich, CT, USA.
Vaena D; OneOncology LLC, Nashville, TN, USA.; West Cancer Center & Research Institute, Germantown, TN, USA.
Staszewski H; OneOncology LLC, Nashville, TN, USA.; New York Cancer & Blood Specialists, Port Jefferson Station, NY, USA.
Fang B; OneOncology LLC, Nashville, TN, USA.; Astera Cancer Care, East Brunswick, NJ, USA.
Seneviratne L; OneOncology LLC, Nashville, TN, USA.; Los Angeles Cancer Network, Los Angeles, CA, USA.
Daniel D; Tennessee Oncology, Nashville, TN, USA.; OneOncology LLC, Nashville, TN, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2024 Jun 03; Vol. 29 (6), pp. 534-542.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Carcinoma, Non-Small-Cell Lung*/mortality
Lung Neoplasms*/drug therapy
Lung Neoplasms*/pathology
Lung Neoplasms*/genetics
Lung Neoplasms*/mortality
Molecular Targeted Therapy*/methods
Oncogenes*
Humans ; Female ; Male ; Middle Aged ; Retrospective Studies ; Aged ; Adult ; Biomarkers, Tumor/genetics ; Aged, 80 and over
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies